Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

Core Points - The Greek Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in high-risk adult patients treated with statins [1][2] - This approval represents the seventh national reimbursement of VAZKEPA® in Europe, enhancing access for eligible patients in Greece [2] - Amarin Corporation has partnered with Vianex S.A. as the exclusive distributor of VAZKEPA® in Greece, with commercialization expected to begin shortly [3][4] Company Overview - Amarin Corporation is focused on advancing cardiovascular disease management and increasing scientific understanding of cardiovascular risk beyond traditional therapies [5] - Vianex S.A. is a leading Greek pharmaceutical company with a 100-year history, involved in the production, import, marketing, and distribution of pharmaceuticals [6][7] Market Context - Cardiovascular diseases are the leading cause of death in Greece, highlighting the importance of new treatment options like VAZKEPA® for improving heart health [2]